Clinical Trial Update: Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003) [Phase 2]

View source ↗

Summary

Extension Phase 2 study assessing long-term safety and effects of luspatercept in myelodysplastic syndromes has completed; results were posted in July 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• REBLOZYL (LUSPATERCEPT)

Snippet

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2024-07-29